Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen is a global biotechnology company that provides integrated solutions for next-generation antibody drug discovery. Founded on proprietary gene-editing technology, the company offers a comprehensive platform that includes the RenMice® (RenMab, RenLite, RenNano) engine for generating fully human antibodies, as well as preclinical validation services, animal model generation, and clinical development support. The company operates as a partner to the global biopharmaceutical industry, collaborating with over 70% of the top 50 pharmaceutical and biotech companies. Biocytogen maintains a dual focus: providing high-quality preclinical services and developing its own internal pipeline of innovative antibody-based therapeutics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), primarily targeting oncology and autoimmune diseases.